HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serum 25-hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with a high risk for fracture.

AbstractBACKGROUND:
Deteriorated quality of life (QOL) is a major problem in osteoporotic women. However, little is known regarding the determinants of QOL in patients with osteoporosis.
OBJECTIVE:
Our aim was to explore the role of vitamin D status on QOL score in osteoporosis with high fracture risk.
METHODS:
Patients were osteoporotic women aged ≥70 years and with ≥1 risk factor for incident fracture, namely prevalent osteoporotic fracture, bone mineral density (BMD) >-3.0 SD of young adult mean, or high bone turnover marker. Health-related QOL was assessed using the Japanese Osteoporosis Quality of Life Questionnaire (JOQOL). When patients were classified into quartiles by total QOL score). Serum 25-hydroxyvitamin D (25[OH]D) level was measured by immunoassay.
RESULTS:
A total of 1585 osteoporotic women were included in the study (age range, 70-95 years). Age, body mass index, serum 25(OH)D status (low, normal, or high), bone mineral density, number of prevalent vertebral fractures, presence of hypertension, presence of osteoarthritis, and history of falls were significantly correlated with QOL quartile. Multivariate liner regression analysis indicated that low serum 25(OH)D level (<20 ng/mL) was an independent determinant of total QOL score quartile (P = 0.0055). The conventional determinants of QOL-age (P < 0.0001), body mass index (P = 0.0060), number of prevalent vertebral fractures (P < 0.0001), presence of osteoarthritis (P = 0.0074), and history of fall (P = 0.0098)-were also independent determinants of total QOL score.
CONCLUSIONS:
These results strongly suggest that low serum 25(OH)D level was a significant determinant of QOL in these osteoporotic women, independently of the conventional factors that reduce QOL. Maintenance of serum 25(OH)D levels >20 ng/mL may be required to maintain patients' QOL in osteoporosis.
AuthorsHiroaki Ohta, Yukari Uemura, Toshitaka Nakamura, Masao Fukunaga, Yasuo Ohashi, Takayuki Hosoi, Satoshi Mori, Toshitsugu Sugimoto, Eiji Itoi, Hajime Orimo, Masataka Shiraki, Adequate Treatment of Osteoporosis (A-TOP) Research Group
JournalClinical therapeutics (Clin Ther) Vol. 36 Issue 2 Pg. 225-35 (Feb 01 2014) ISSN: 1879-114X [Electronic] United States
PMID24462224 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 The Authors. Published by EM Inc USA.. All rights reserved.
Chemical References
  • Vitamin D
  • 25-hydroxyvitamin D
Topics
  • Aged
  • Aged, 80 and over
  • Body Mass Index
  • Bone Density
  • Female
  • Humans
  • Multivariate Analysis
  • Osteoporosis, Postmenopausal (blood, complications)
  • Quality of Life
  • Spinal Fractures (etiology, psychology)
  • Surveys and Questionnaires
  • Vitamin D (analogs & derivatives, blood)
  • Women's Health

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: